癌症治疗中碘-131与碘-131-间碘苄胍的剂量测定
放射性碘用于治疗良性甲状腺疾病和甲状腺癌已80年,碘-131-间碘苄胍(I-131 mIBG)后来用于治疗成人和儿童神经内分泌肿瘤。固定活度方法导致靶体积和正常器官的吸收剂量范围很宽,基于剂量测定的个体化治疗计划现已技术可行,多中心临床试验及图像定量、生物动力学建模和放射生物学研究正在进行中。
要点
- 固定活度方法导致靶体积和正常器官的吸收剂量范围很宽。
- 骨髓剂量测定的挑战通过替代指标应对,甲状腺治疗常用血液剂量,I-131 mIBG治疗神经母细胞瘤用全身剂量。
- 个体化治疗计划现已技术可行,多中心临床试验及图像定量、生物动力学建模和放射生物学研究正在进行中。
核心结论
- 固定活度方法导致靶体积和正常器官的吸收剂量范围很宽。
- 个体化治疗计划现已技术可行,多中心临床试验及图像定量、生物动力学建模和放射生物学研究正在进行中。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 物理学家从最初就密切参与测量滞留、定量摄取和计算辐射剂量测定。
- 随着治疗广泛开展,采用了对比鲜明的治疗方案,或给予经验推导的固定活度水平,或根据所给辐射剂量进行指导。
- 与体外束放疗类似,基于最大化靶体积辐射剂量同时限制危及器官特别是骨髓辐射剂量的目标,开发了甲状腺癌和神经内分泌肿瘤的个体化治疗。
- 骨髓剂量测定的挑战通过使用替代指标应对,甲状腺治疗常用血液剂量,I-131 mIBG治疗神经母细胞瘤时用全身剂量。
- 多项研究试图建立确保疗效的阈值吸收剂量,尽管提出了不同数值,但已确凿证明固定活度方法导致靶体积和正常器官的吸收剂量范围很宽。
关键数值与推荐
- 原文未报告具体阈值吸收剂量数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radioactive iodine was first used for the treatment of benign thyroid disease and thyroid cancer 80 years ago. I-131 mIBG was later developed for the treatment of adult and pediatric neuroendocrine tumors. Physicists were closely involved from the outset to measure retention, to quantify uptake and to calculate radiation dosimetry. As the treatment became widespread, contrasting treatment regimes were followed, either given with empirically derived fixed levels of activity or guided according to the radiation doses delivered. As for external beam radiotherapy, individualized treatments for both thyroid cancer and neuroendocrine tumors were developed based on the aim of maximizing the radiation doses delivered to target volumes while restricting the radiation doses delivered to organs-at-risk, particularly the bone marrow. The challenge of marrow dosimetry has been met by using surrogate measures, often the blood dose for thyroid treatments and the whole-body dose in the case of treatment of neuroblastoma with I-131 mIBG. A number of studies have sought to establish threshold absorbed doses to ensure therapeutic efficacy. Although different values have been postulated, it has nevertheless been conclusively demonstrated that a fixed activity approach leads to a wide range of absorbed doses delivered to target volumes and to normal organs. Personalized treatment planning is now technically feasible with ongoing multicenter clinical trials and investigations into image quantification, biokinetic modelling and radiobiology.
引用
- Flux G, Leek F, Gape P, et al. Iodine-131 and Iodine-131-Meta-iodobenzylguanidine Dosimetry in Cancer Therapy. Semin Nucl Med. 2021. PMID: 34961618. doi:10.1053/j.semnuclmed.2021.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。